According to BlockBeats, Hong Kong-listed Huajian Medical has announced a strategic partnership with Transcenta Group Pharmaceutical Co., Ltd. and its subsidiary Transcenta Oncology Inc. The agreement, valued at $1.5 billion, involves the tokenization of innovative drug pipeline assets through RWA tokens. Huajian Medical, along with its subsidiaries ETHK Inc and ETHK Holdings Limited, will collaborate with Transcenta to explore the potential of this venture.
Hong Kong's Huajian Medical Signs $1.5 Billion Strategic Partnership for Tokenization of Drug Assets
--・
AI Summary
Disclaimer: Includes third-party opinions. No financial advice. May include sponsored content. See T&Cs.
